282 related articles for article (PubMed ID: 18653333)
1. 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
Xu G; Abad MC; Connolly PJ; Neeper MP; Struble GT; Springer BA; Emanuel SL; Pandey N; Gruninger RH; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2008 Aug; 18(16):4615-9. PubMed ID: 18653333
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
3. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
Suzuki N; Shiota T; Watanabe F; Haga N; Murashi T; Ohara T; Matsuo K; Omori N; Yari H; Dohi K; Inoue M; Iguchi M; Sentou J; Wada T
Bioorg Med Chem Lett; 2012 Jan; 22(1):456-60. PubMed ID: 22101132
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
Waterson AG; Petrov KG; Hornberger KR; Hubbard RD; Sammond DM; Smith SC; Dickson HD; Caferro TR; Hinkle KW; Stevens KL; Dickerson SH; Rusnak DW; Spehar GM; Wood ER; Griffin RJ; Uehling DE
Bioorg Med Chem Lett; 2009 Mar; 19(5):1332-6. PubMed ID: 19208477
[TBL] [Abstract][Full Text] [Related]
6. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
[TBL] [Abstract][Full Text] [Related]
7. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.
Li S; Guo C; Zhao H; Tang Y; Lan M
Bioorg Med Chem; 2012 Jan; 20(2):877-85. PubMed ID: 22182581
[TBL] [Abstract][Full Text] [Related]
9. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
11. A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity.
Hughes TV; Xu G; Wetter SK; Connolly PJ; Emanuel SL; Karnachi P; Pollack SR; Pandey N; Adams M; Moreno-Mazza S; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Sep; 18(17):4896-9. PubMed ID: 18678484
[TBL] [Abstract][Full Text] [Related]
12. Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
Hubbard RD; Dickerson SH; Emerson HK; Griffin RJ; Reno MJ; Hornberger KR; Rusnak DW; Wood ER; Uehling DE; Waterson AG
Bioorg Med Chem Lett; 2008 Nov; 18(21):5738-40. PubMed ID: 18842405
[TBL] [Abstract][Full Text] [Related]
13. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Waterson AG; Stevens KL; Reno MJ; Zhang YM; Boros EE; Bouvier F; Rastagar A; Uehling DE; Dickerson SH; Reep B; McDonald OB; Wood ER; Rusnak DW; Alligood KJ; Rudolph SK
Bioorg Med Chem Lett; 2006 May; 16(9):2419-22. PubMed ID: 16483772
[TBL] [Abstract][Full Text] [Related]
14. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Petrov KG; Zhang YM; Carter M; Cockerill GS; Dickerson S; Gauthier CA; Guo Y; Mook RA; Rusnak DW; Walker AL; Wood ER; Lackey KE
Bioorg Med Chem Lett; 2006 Sep; 16(17):4686-91. PubMed ID: 16777410
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors.
Suzuki N; Shiota T; Watanabe F; Haga N; Murashi T; Ohara T; Matsuo K; Oomori N; Yari H; Dohi K; Inoue M; Iguchi M; Sentou J; Wada T
Bioorg Med Chem Lett; 2011 Mar; 21(6):1601-6. PubMed ID: 21334203
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
17. New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Mastalerz H; Chang M; Chen P; Dextraze P; Fink BE; Gavai A; Goyal B; Han WC; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Ruediger E; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
Bioorg Med Chem Lett; 2007 Apr; 17(7):2036-42. PubMed ID: 17270437
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
[TBL] [Abstract][Full Text] [Related]
19. 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors.
Gaul MD; Xu G; Kirkpatrick J; Ott H; Baumann CA
Bioorg Med Chem Lett; 2007 Sep; 17(17):4861-5. PubMed ID: 17611106
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.
Kawakita Y; Miwa K; Seto M; Banno H; Ohta Y; Tamura T; Yusa T; Miki H; Kamiguchi H; Ikeda Y; Tanaka T; Kamiyama K; Ishikawa T
Bioorg Med Chem; 2012 Oct; 20(20):6171-80. PubMed ID: 22980219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
